News

Endpoints News5m
Take­da an­nounces hand­ful of pipeline cuts in ef­fort to ‘piv­ot re­sources’
Takeda revealed a handful of pipeline cuts in its fourth-quarter earnings results on Thursday, as the company focuses its ...
Endpoints News14m
Il­lu­mi­na fore­casts $85M in tar­iff costs, de­crease in Chi­na sales
Illumina estimates about $85 million in costs this year related to tariffs on its DNA sequencing products, the company said ...
Endpoints News1h
AI-fo­cused biotech in­sitro cuts 22% of staff, cit­ing 'tu­mul­tuous mar­ket'
The AI-fo­cused biotech in­sitro has laid off 22% of its work­force, the com­pa­ny said in a Thurs­day state­ment. Found­ed ...
Endpoints News2h
As­traZeneca los­es ap­peals court fight over IRA drug price ne­go­ti­a­tions
AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...
Endpoints News2h
GSK awaits Nu­cala de­ci­sion af­ter FDA tar­get date pass­es
The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease ...
Endpoints News2h
FDA grants Ve­rastem first ap­proval for rare ovar­i­an can­cer treat­ment
Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...
Endpoints News5h
Blood can­cer biotech Vor Bio ends clin­i­cal work, lays off 95% of staff
Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...
Endpoints News6h
'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis
Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher ...